Skip to content

Goodwill at other companies

Pfizer logo
PfizerPFE
$71.41B+4.3%
McKesson logo
McKessonMCK
$11.32B+12.9%
Cencora logo
CencoraCOR
$16.45B+16.8%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$1.81B+2.6%
AbbVie logo
AbbVieABBV
$35.57B+0.8%
Cardinal Health logo
Cardinal HealthCAH

Segments

By segment

See full
Specialty$366.31M0.0%
Affordable Medicines$158.02M
AvKARE$69.47M0.0%

Other financials

Income statement

See full
Revenue$722.5M+3.9%
Gross profit$320.1M+25.1%
Operating income$141.8M+41.3%
Net income$62.3M+411%
EPS (diluted)$0.19+375%

Balance sheet

See full
Cash & equivalents$197.7M+234%
Total debt$2.6B+17.7%
Total equity-$45.4M+65.5%
Total assets$3.5B+5.2%

Cash flow

See full
Operating cash flow-$26.7M-461%
CapEx$8.2M-37.9%
Free cash flow-$34.9M-507%

Valuation

See full
Market cap$5.17B+51.0%

Profitability

See full
Gross margin38.7%+2.0pp
Operating margin14.3%+1.6pp
Net margin4%+3.6pp
FCF margin7.9%-1.0pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity127.9×+119×
Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s goodwill?
Amneal Pharmaceuticals, Inc. (AMRX) reported goodwill of $593.8M in Q1 2026.
How has Amneal Pharmaceuticals, Inc.'s goodwill changed year-over-year?
Amneal Pharmaceuticals, Inc.'s goodwill decreased by 0.6% year-over-year, from $597.5M to $593.8M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s goodwill?
Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s goodwill has grown at a 2.6% compound annual growth rate (CAGR), from $522.81M to $595.47M.
What does goodwill mean?
The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.